HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GSK Rejects £50bn Bid For Consumer Healthcare From Unilever

Executive Summary

GSK says London-based Unilever's £50bn bid for Consumer Healthcare fundamentally undervalues a business which generated sales close to £10bn last year and is expected to grow 4-6% over the medium term. The rejection has not dissuaded Unilever, however, with the company intent on stepping up its presence in the health, beauty and hygiene categories.

You may also be interested in...



Unilever Vows No GSK-Sized Ventures For Foreseeable Future, Commits To Existing Brands In 2022

Opening the company’s fiscal 2021 full-year earnings call, Unilever leadership assured investors it will not make any GSK-sized offers in the foreseeable future as it commits to organic growth and reshaping its portfolio more surgically through bolt-on deals and selective disposals.

Unilever’s Sale Of Thailand Direct Selling Business Doesn’t Quiet Investors Calling For Change

Response to sale of Unilever’s direct selling business in Thailand, Unilever Life, like its recent failed bid for GSK consumer and its elimination of 1,500 management staff, exposes disconnect between its priorities and its shareholders preferences.

Sanofi Not Distracted By M&A Chatter As It Gets Back On Par With Market Growth

Recent market interest shown in other OTC assets will not distract Sanofi from its long-term plan to overhaul its Consumer Healthcare business, says CEO Paul Hudson. And this plan is delivering results, with Sanofi back on par with the consumer health market, posting sales up by 5% in 2021.

Related Content

Topics

UsernamePublicRestriction

Register

RS152115

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel